Cite

HARVARD Citation

    Hellmann, J. et al. (2021). Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease. Pediatric quality & safety. 6 (3), pp. e400-. [Online]. 
  
Back to record